Statin Therapy for Patients with Cardiovascular Disease: Assesses males 21–75 years of age and females 40–75 years of age who have clinical atherosclerotic cardiovascular disease (ASCVD) and who received and adhered to statin therapy.
Statin Therapy for Patients with Diabetes: Assesses adults 40-75 years of age who have diabetes and who do not have clinical ASCVD, who received and adhered to statin therapy.
Why it Matters
Cardiovascular disease is the leading cause of death in the United States. It is estimated that 92.1 million American adults have one or more types of cardiovascular disease (Benjamin et al., 2017). People with diabetes also have elevated cardiovascular risk, thought to be due in part to elevations in unhealthy cholesterol levels. Having unhealthy cholesterol levels places people at significant risk for developing ASCVD.
Statins are a class of drugs that lower blood cholesterol. American College of Cardiology and American Heart Association (ACC/AHA) guidelines state that statins of moderate or high intensity are recommended for adults with established clinical ASCVD. The American Diabetes Association and ACC/AHA guidelines also recommend statins for primary prevention of cardiovascular disease in patients with diabetes, based on age and other risk factors. Guidelines also state that adherence to statins will aid in ASCVD risk reduction in both populations.
Results – National Averages
Statin Therapy for Patients with Diabetes- Received Statin Therapy
| Measure Year | Commercial HMO | Commercial PPO | Medicaid HMO | Medicare HMO | Medicare PPO |
|---|---|---|---|---|---|
| 2022 | 65.4 | 63.3 | 63.8 | 79.2 | 77 |
| 2021 | 66.1 | 64.5 | 64.7 | 79 | 76.6 |
| 2020 | 65.1 | 63.8 | 64.3 | 77.9 | 75.2 |
| 2019 | 64.0 | 62.5 | 64.0 | § | § |
| 2018 | 63.0 | 61.0 | 62.3 | 74.4 | 71.3 |
| 2017 | 61.5 | 60.1 | 61.4 | 72.3 | 69.6 |
| 2016 | 60.2 | 58.9 | 60.2 | 70.7 | 67.8 |
Statin Therapy for Patients with Diabetes- Statin Adherence 80%
| Measure Year | Commercial HMO | Commercial PPO | Medicaid HMO | Medicare HMO | Medicare PPO |
|---|---|---|---|---|---|
| 2022 | 72 | 76.7 | 66.1 | 83.8 | 84.3 |
| 2021 | 72.5 | 76 | 66.2 | 82.8 | 83.6 |
| 2020 | 73.4 | 76.5 | 68.7 | 83.8 | 85.3 |
| 2019 | 70.4 | 73.5 | 64.1 | § | § |
| 2018 | 70.1 | 71.0 | 61.1 | 78.4 | 79.7 |
| 2017 | 66.5 | 67.7 | 59.0 | 74.0 | 75.2 |
| 2016 | 66.5 | 67.5 | 59.3 | 75.3 | 77.6 |
Statin Therapy for Patients with Cardiovascular Disease- Received Statin Therapy
| Measure Year | Commercial HMO | Commercial PPO | Medicaid HMO | Medicare HMO | Medicare PPO |
|---|---|---|---|---|---|
| 2022 | 81.9 | 81.8 | 78.7 | 85.4 | 84.2 |
| 2021 | 82.5 | 81.9 | 78.5 | 84.7 | 83.8 |
| 2020 | 81.8 | 81.3 | 78.3 | 83.6 | 82.6 |
| 2019 | 81.9 | 80.8 | 78.0 | § | § |
| 2018 | 80.7 | 80.4 | 76.3 | 81.1 | 80.4 |
| 2017 | 80.4 | 80.9 | 76.1 | 79.0 | 79.1 |
| 2016 | 79.2 | 79.9 | 74.7 | 77.3 | 76.8 |
Statin Therapy for Patients with Cardiovascular Disease- Statin Adherence 80%
| Measure Year | Commercial HMO | Commercial PPO | Medicaid HMO | Medicare HMO | Medicare PPO |
|---|---|---|---|---|---|
| 2022 | 77.6 | 81.4 | 69.9 | 85 | 86 |
| 2021 | 78.2 | 81.4 | 70.2 | 84.7 | 85.6 |
| 2020 | 78.9 | 81.2 | 71.6 | 85.0 | 86.7 |
| 2019 | 76.6 | 79.5 | 67.8 | § | § |
| 2018 | 75.9 | 76.7 | 64.6 | 80.4 | 81.2 |
| 2017 | 73.5 | 75.3 | 63.0 | 76.3 | 77.8 |
| 2016 | 69.8 | 72.0 | 60.9 | 75.5 | 76.7 |
§ Not available due to CMS suspension of data reporting during COVID-19 pandemic.
This State of Healthcare Quality Report classifies health plans differently than NCQA’s Quality Compass. HMO corresponds to All LOBs (excluding PPO and EPO) within Quality Compass. PPO corresponds to PPO and EPO within Quality Compass.
Figures do not account for changes in the underlying measure that could break trending. Contact Information Products via my.ncqa.org for analysis that accounts for trend breaks.
References
- Benjamin, E.J., et al. 2017. “Heart disease and stroke statistics-2017 update: a report from the American Heart Association.” Circulation 135(10): e146–e603. doi:10.1161/CIR.0000000000000485.